Núñez AMA

Language: Spanish
References: 10
Page: s110-112
PDF size: 272.28 Kb.

REFERENCES

1. Red Cell Immunogenetics and Blood Group Terminology. Available in: https://www.isbtweb.org/isbt-working-parties/rcibgt.html

2. Pirenne F, Pondarré C. Alloimmunization and hyperhemolysis in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2023; 2023 (1): 653-659.

3. Hendrickson JE. Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. Ann Blood. 2020; 5: 33.

4. Transfusion/donation fatalities. Available in: https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/transfusiondonation-fatalities

5. Gehrie EA, Ness PM, Bloch EM, Kacker S, Tobian AAR. Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. Transfusion. 2017; 57 (9): 2267-2276.

6. Viayna E, Gehrie EA, Blanchette C, Meny GM, Noumsi G, Huber M et al. Red cell alloimmunization is associated with increased health care costs, longer hospitalizations, and higher mortality. Blood Adv. 2022; 6 (20): 5655-5658.

7. Viayna E, Gehrie EA, Blanchette C. Alloimmunization in myelodysplastic syndrome is associated with higher healthcare costs, longer hospitalizations, and increased mortality. Transfusion. 2024; 64 (9): 1640-1647.

8. Castilho L. Molecular typing of blood group genes in diagnostics. Ann Blood. 2021; 6: 20.

9. Abdel-Messih IY, Mahmoud HM, Habashy DMM. Prevalence of red cell allo-antibodies among muti-transfused autoimmune hemolytic anemia Egyptian patients. Journal of Applied H. 2014; 5 (3).

10. Nance S, Scharberg EA, Thornton N, Yahalom V, Sareneva I, Lomas-Francis C. International rare donor panels: a review. Vox Sang. 2016; 110 (3): 209-218.